References
- Walsh G. Biopharmaceutical benchmarks. Nat Biotechnol. 2000;18:831–833.
- Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7:21–39.
- Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol. 2014;32:992–1000.
- U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research List of Licensed Biological Products. 2017. cited 2017 Jul 25 Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM560162.pdf
- European Medicines Agency. European public assessment reports for human medicines. 2017. cited 2017 Jul 25 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&startLetter=View+all&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=generics
- World Health Organization. Guidelines on evaluation of similar biotherapeutic products. 2009. cited 2017 Jul 25 Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
- European Medicines Agency. Guideline on similar biological medicinal products. 2014. cited 2017 Jul 25 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
- U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry scientific consideration in demonstration biosimilarity to a Reference Product. 2015. cited 2017 Jul 25 Available from: https://www.fda.gov/downloads/drugsguidancecomplianceregulatoryinformation/guidances/ucm291128.pdf
- European Medicines Agency. European public assessment report Omnitrope. 2008. cited 2017 Jul 23 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000607/WC500043689.pdf
- U.S. Department of Health and Human Services, Food and Drug Administration. Approval letter Zarxio. 2015. cited 2017 Sept 01 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000Approv.pdf
- Generics and Biosimilars Initiative. Biosimilars approved in Europe. 2017. cited 2017 Sept 01 Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
- Generics and Biosimilars Initiative. Biosimilars approved in the U.S. 2017. cited 01 September 2017 Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-the-US
- Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol. 2006;24:1241–1252.
- Berkowitz SA, Engen JR, Mazzeo JR, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11:527–540.
- International Conference of Harmonization Guideline. Pharmaceutical development Q8(R2). 2009. cited 2017 Jul 25 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf
- Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004;22:1383–1391.
- Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310–312.
- Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72:315–318.
- Vezér B, Buzás Z, Sebeszta M, et al. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin. 2016;32:829–834.
- International Conference of Harmonization Guideline. Comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E. 2004. cited 2017 Jul 25 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf
- Graham J, Muhsin M, Kirkpatrick P. Cetuximab. Nat Rev Drug Discov. 2004;3:549–550.
- U.S. Department of Health and Human Services, Food and Drug Administration. Erbitux label. 2012. cited 2017 Jul 25 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s0228lbl.pdf
- European Medicines Agency. Summary of product characteristics Erbitux. 2015. cited 2017 Jul 23 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119.pdf
- Cohen MH, Chen H, Shord S, et al. Approval summary: cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist. 2013;18:460–466.
- Soulières D, Aguilar JL, Chen E, et al. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen. BMC Cancer. 2016;16:19.
- Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011;25:491–502.
- Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938–952.
- U.S. Department of Health and Human Services, Food and Drug Administration. Avonex label. 2012. cited 2017 Jul 25 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103628s5189lbl.pdf
- European Medicines Agency. Summary of product characteristics Avonex. 2017. cited 2017 Jul 25 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000102/WC500029425.pdf
- U.S. Department of Health and Human Services, Food and Drug Administration. Rebif label. 2015. cited 2017 Jul 25 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103780s5194lbl.pdf
- European Medicines Agency. Summary of product characteristics Rebif. 2017. cited 2017 Jul 23 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf
- Bertolotto A, Deisenhammer F, Gallo P, et al. Immunogenicity of interferon beta: differences among products. Neurol. 2004;251:15–24.
- Manfredonia F, Pasquali L, Dardano A, et al. Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2008;4:321–336.
- Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2009;15:219–228.
- Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med. 2014;370:1270–1271.
- Ben-Amor AF, Trochanov A, Fischer TZ. Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome reports with subcutaneous interferon β-1a. Adv Ther. 2015;32:445–454.
- Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–475.
- McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48:1754–1762.
- Boven K, Knight J, Bader F, et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant. 2005;20:33–40.
- Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67:2346–2353.
- Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403–1408.
- Macdougall IC, Casadevall N, Locatelli F, et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant. 2015;30:451–460.
- Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem. 2012;84:4637–4646.
- Beck A, Debaene F, Diemer H, et al. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. Mass Spectrom. 2015;50:285–297.
- Melmer M, Stangler T, Schiefermeier M, et al. HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals. Anal Bioanal Chem. 2010;398:905–914.
- Houel S, Hilliard M, Yu YQ, et al. N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality. Anal Chem. 2014;86:576–584.
- Shang TQ, Saati A, Toler KN, et al. Development and application of a robust N-glycan profiling method for heightened characterization of monoclonal antibodies and related glycoproteins. J Pharm Sci. 2014;103:1967–1978.
- Brady LJ, Martinez T, Balland A. Characterization of nonenzymatic glycation on a monoclonal antibody. Anal Chem. 2007;79:9403–9413.
- Brady LJ, Scott RA, Balland A. An optimized approach to the rapid assessment and detection of sequence variants in recombinant protein products. Anal Bioanal Chem. 2015;407:3851–3860.
- Yu XC, Joe K, Zhang Y, et al. Accurate determination of succinimide degradation products using high fidelity trypsin digestion peptide map analysis. Anal Chem. 2011;83:5912–5919.
- Hausberger A, Lamanna WC, Hartinger M, et al. Identification of low-level product-related variants in filgrastim products presently available in highly regulated markets. BioDrugs. 2016;30:233–242.
- Wang Y, Li X, Liu YH, et al. Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion. MAbs. 2016;8:1477–1486.
- Cheng Y, Chen MT, Patterson LC, et al. Domain-specific free thiol variant characterization of an IgG1 by reversed-phase high-performance liquid chromatography mass spectrometry. Anal Biochem. 2017;519:8–14.
- Lamanna WC, Mayer RE, Rupprechter A, et al. The structure-function relationship of disulfide bonds in etanercept. Sci Rep. 2017;7:3951.
- Reisinger V, Toll H, Mayer RE, et al. A mass spectrometry-based approach to host cell protein identification and its application in a comparability exercise. Anal Biochem. 2014;463:1–6.
- Walker DE, Yang F, Carver J, et al. A modular and adaptive mass spectrometry-based platform for support of bioprocess development toward optimal host cell protein clearance. MAbs. 2017;9:654–663.
- Forstenlehner IC, Holzmann J, Scheffler K, et al. A direct-infusion- and HPLC-ESI-Orbitrap-MS approach for the characterization of intact PEGylated proteins. Anal Chem. 2014;86:826–834.
- Forstenlehner IC, Holzmann J, Toll H, et al. Site-specific characterization and absolute quantification of pegfilgrastim oxidation by top-down high-performance liquid chromatography-mass spectrometry. Anal Chem. 2015;87:9336–9343.
- Holzmann J, Hausberger A, Rupprechter A, et al. Top-down MS for rapid methionine oxidation site assignment in filgrastim. Anal Bioanal Chem. 2013;405:6667–6674.
- Haberger M, Heidenreich AK, Schlothauer T, et al. Functional assessment of antibody oxidation by native mass spectrometry. MAbs. 2015;7:891–900.
- Haberger M, Leiss M, Heidenreich AK, et al. Rapid characterization of biotherapeutic proteins by size-exclusion chromatography coupled to native mass spectrometry. MAbs. 2016;8:331–339.
- Gahoual R, Heidenreich AK, Somsen GW, et al. Detailed characterization of monoclonal antibody receptor interaction using affinity liquid chromatography hyphenated to native mass spectrometry. Anal Chem. 2017;89:5404–5412.
- Leblanc Y, Ramon C, Bihoreau N, et al. Charge variants characterization of a monoclonal antibody by ion exchange chromatography coupled on-line to native mass spectrometry: case study after a long-term storage at +5°C. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1048:130–139.
- Wang G, De Jong RN, Van den Bremer ETJ, et al. Enhancing accuracy in molecular weight determination of highly heterogeneously glycosylated proteins by native tandem mass spectrometry. Anal Chem. 2017;89:4793–4797.
- Rogers RS, Nightlinger NS, Livingston B, et al. Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics. MAbs. 2015;7:881–890.
- International Conference of Harmonization Guideline. Good manufacturing practice guide for active pharmaceutical ingredients Q7. 2000. cited 2017 Jul 25 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf
- U.S. Department of Health and Human Services, Food and Drug Administration. Pharmaceutical cGMPs for the 21st century – a risk based approach. 2004. cited 2017 Aug 28 Available from: https://www.fda.gov/downloads/drugs/developmentapprovalprocess/manufacturing/questionsandanswersoncurrentgoodmanufacturingpracticescgmpfordrugs/ucm176374.pdf
- International Conference of Harmonization Guideline. Pharmaceutical quality system Q10. cited 2017 Jul 25 2008. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf
- International Conference of Harmonization Guideline. Quality risk management Q9. 2005. cited 2017 Jul 25 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf
- International Conference of Harmonization Guideline. Development and manufacture of drug substances Q11. 2012. cited 2017 Jul 25 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf
- International Conference of Harmonization Guideline. Specifications: test procedures and acceptance criteria for biotechnological/biological products Q6B. 1999. cited 2017 Jul 25 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
- U.S. Department of Health and Human Services, Food and Drug Administration. FDA Guidance for industry process validation general principles and practices. 2011. cited 2017 Jul 25 Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm070336.pdf
- European Medicines Agency. Guideline on process validation for finished products – information and data to be provided in regulatory submissions. 2016. cited 2017 Jul 25 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162136.pdf
- U.S. Department of Health and Human Services, Food and Drug Administration. FDA Guidance for industry analytical procedures and methods validation for drugs and biologics. 2015. cited 2017 Jul 25 Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm386366.pdf
- Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28:363–372.
- European Medicines Agency. European public assessment reports for Aranesp. 2008. cited 2017 Jul 25 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000332/WC500026148.pdf
- Kim S, Song J, Park S, et al. Drifts in ADCC-related quality attributes of Herceptin®: impact on development of a trastuzumab biosimilar. MAbs. 2017;9:704–714.
- U.S. Department of Health and Human Services, Food and Drug Administration. FDA guidance for industry Q5E Comparability of biotechnological/biological products subject to changes in their manufacturing process. 2005. cited 2017 Jul 25 Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm073476.pdf
- European Medicines Agency. Guideline on comparability of biotechnology derived medicinal products after a change in the manufacturing process. 2007. cited 2017 Jul 25 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003935.pdf
- Webster CJ, Woollett GR. A ‘global reference’ comparator for biosimilar development. BioDrugs. 2017;31:279–286.
- Tebbey PW, Varga A, Naill M, et al. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). MAbs. 2015;7:805–811.
- Kurki P, Van Aerts L, Wolff-Holz E, et al. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31:83–91.
- Lemery SJ, Ricci MS, Keegan P, et al. FDA’s approach to regulating biosimilars. Clin Cancer Res. 2017;23:1882–1885.